Novo CEO Brushes Off Post-Midterm Drug-Pricing Fears, Says ‘Our World’ Won’t Change Dramatically – NVO Stock Gains Pre-Market
CEO Mike Doustdar told CNBC that while the company has experienced weak growth in the past due to pricing, volumes have grown ‘phenomenally.’